University of Ioannina
Effect of SGLT-2 inhibitors on the serum and urine metabolome in patients with type 2 diabetes mellitus
Abstract
dc:descriptionBackground and aims: Type 2 Diabetes Mellitus is increasing worldwide and is regarded as the next pandemic. Patients with type 2 diabetes are at an increased risk of microvascular and macrovascular complications including coronary heart disease, stroke, peripheral arteriopathy, chronic kidney disease and others. Inhibitors of Sodium-Glucose co-transporter 2 (SGLT-2), including empagliflozin, dapagliflozin and canagliflozin have shown promising results in reducing overall mortality, cardiovascular disease as well as progression of kidney disease in patients with type 2 diabetes mellitus. Furthermore, these agents have been recently approved for patients with heart failure and chronic kidney disease irrespective of the presence of diabetes. The underlying mechanisms include improvement in energy homeostasis and reduced insulin resistance, although the exact mechanisms have yet to be elucidated. We aimed to examine the underlying mechanisms of cardiac and renal protection of SGLT-2 inhibitors in patients with type 2 diabetes using 1H-NMR based metabolomics. Materials and methods: Eighty patients with type 2 diabetes mellitus on metformin monotherapy and HbA1c > 7% were included in the study. Fifty patients received dapagliflozin 10 mg daily and thirty patients received insulin degludec which was uptitrated every 3 days to a target fasting glucose of 100-120 mg/dl. Serum and urine samples were acquired prior to and after 3 months of treatment initiation. 1H-NMR based metabolomics was performed for serum and urine samples before and after treatment initiation. Results: Eighty patients were included in the study, 50 on the dapagliflozin arm and 30 on the insulin arm. All patients completed successfully the treatment period. Demographics, diabetes duration, weight, body mass index and blood pressure were similar between groups. Dapagliflozin administration decreased body weight and BMI, systolic and diastolic blood pressure. Glucose and HbA1c levels decreased in both groups without between group difference. Dapagliflozin increased serum phosphate, serum magnesium and hemoglobin levels, while uric acid levels decreased. Urine uric acid was increased following dapagliflozin administration. Untargeted metabolomics showed good separation in the dapagliflozin arm before and after 3 months in both serum and urine, while in the insulin arm no separation was evident. Targeted metabolomics revealed that dapagliflozin induced a minor but significant change in serum metabolomics compared with insulin, while a more profound change was noted in urine metabolomics. Increased ketone levels and better energy homeostasis may account for the aforementioned clinical effects of dapagliflozin administration. Conclusion: Dapagliflozin administration led to changes in the serum and urine metabolome that indicate improvement in energy homeostasis at a whole body level. Furthermore, changes that indicate decreased inflammatory activity and reduced insulin resistance after dapagliflozin administration were found.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Filippas-Ntekouan, Sempastian
- Φίλιππας-Ντεκουάν, Σεμπάστιαν
Subjects
dc:subject × 20- Αναστολείς SGLT-2
- Μεταβολομική
- Δαπαγλιφλοζίνη
- Καρδιοπροστασία
- Νεφροπροστασία
- SGLT-2 inhibitors
- Metabolomics
- Dapagliflozin
- Cardioprotection
- Renoprotection
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Βασική Ιατρική
- Ιατρική βιοχημεία
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
- Basic Medicine
- Medical Biochemistry
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57793